Hydrocortisone Sodium Succinate

Phase 3Small molecule

Hydrocortisone Sodium Succinate is one of 120 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoblastic LeukemiaActive, not recruiting

Septic ShockRecruiting

Acute Leukemia of Ambiguous LineageActive, not recruiting

Adult T Acute Lymphoblastic LeukemiaActive, not recruiting

Recurrent Childhood Acute Myeloid LeukemiaRecruiting

Down SyndromeRecruiting

Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Septic ShockPhase 3

Recruiting

Acute Leukemia of Ambiguous LineagePhase 2

Active, not recruiting

Adult T Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Recurrent Childhood Acute Myeloid LeukemiaPhase 1

Recruiting

Down SyndromePhase 2

Recruiting

Competition

Competitive Landscape

163 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

75 2

Adriamycin

Pfizer

Phase 3

40 3

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

40 4

Elspar

DDutch Childhood Oncology Group

Phase 3

45 5

Oncaspar

SServier

Phase 3

48 6

Fludara

Sanofi

Phase 3

15 7

Cellcept

Roche

Phase 3

11 8

Neoral

Novartis

Phase 3

10 9

Arranon

Novartis

Phase 3

7 10

Jakafi

Incyte

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT02883049

Phase 3Recruiting

Septic Shock

NCT03401398

Q4 2027

Phase 2Active, not recruiting

Acute Leukemia of Ambiguous Lineage

NCT05761171

Q1 2028

Phase 1Recruiting

Recurrent Childhood Acute Myeloid Leukemia

NCT06247787

Q2 2028

Phase 2Recruiting

Down Syndrome

NCT04546399

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia4 trials

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT00720109·63 enrolled

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02828358·78 enrolled

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02883049·5,949 enrolled

Show 1 more trial

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01005758·180 enrolled

Leukemia2 trials

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Withdrawn·CChildren's Oncology Group·Phase 1/2·NCT05320380

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00057811·97 enrolled

Septic Shock2 trials

Stress Hydrocortisone In Pediatric Septic Shock

Recruiting·JJerry Zimmerman·Phase 3·NCT03401398·500 enrolled

Corticosteroid Therapy of Septic Shock - Corticus

Completed·HHadassah Medical Organization·Phase 3·NCT00147004·500 enrolled

Adult ALL1 trial

ALL Adult Consortium Trial: Adult ALL Trial

Completed·—·Phase 2·NCT00476190·112 enrolled

Glucocorticoids1 trial

Prospective Randomized Study of Glucocorticoids in the Impact of the Liver Function and the Prognosis After Hepatectomy of HCC

Suspended·—··NCT01608945·60 enrolled

6 more indications

After Cardiac Surgery1 trial

Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS)

Unknown status·IInstituto do Coracao·Phase 3·NCT04301479·140 enrolled

Ulcerative Colitis1 trial

Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis

Unknown status·XXijing Hospital of Digestive Diseases·Phase 4·NCT03110198·528 enrolled

Down syndrome1 trial

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04546399·461 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT05761171·78 enrolled

Recurrent Childhood Acute Myeloid Leukemia1 trial

A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy

Recruiting·CChildren's Oncology Group·Phase 1·NCT06247787·36 enrolled

Adult T Acute Lymphoblastic Leukemia1 trial

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02112916·847 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Hydrocortisone Sodium Succinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydrocortisone Sodium Succinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydrocortisone Sodium Succinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

Hydrocortisone Sodium Succinate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Acute Lymphoblastic Leukemia4 trials

Leukemia2 trials

Septic Shock2 trials

Adult ALL1 trial

Glucocorticoids1 trial

After Cardiac Surgery1 trial

Ulcerative Colitis1 trial

Down syndrome1 trial

Acute Leukemia of Ambiguous Lineage1 trial

Recurrent Childhood Acute Myeloid Leukemia1 trial

Adult T Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News